

Date: - August 13, 2026

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex Bandra (E),
Mumbai – 400051

Scrip Code: SUNREST

Subject: - Newspaper Publication

Dear Sir/Ma'am,

In compliance with Regulation 84 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "SEBI ICDR Regulations") and Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations") please find enclosed herewith the copies of newspaper publications made by the Company on August 13, 2026, in terms of regulation 84(1) of the SEBI ICDR Regulations, as amended informing shareholders about the dispatch of Letter of Offer, Rights Entitlement Letter, Application Form and Other Issuer Related Information, in following newspapers:-

Name of the Newspaper	Language	Edition
Financial Express	English	All Edition
Jansatta	Hindi	All Edition
Financial Express	Gujarati	Ahmedabad Edition

Kindly take the same in your record.

Thanking You,

Yours Faithfully,
For, Sunrest Lifescience Limited

NIKHILKUMAR
YASHVNTLAL
THAKKAR
Digitally signed by
NIKHILKUMAR YASHVNTLAL
THAKKAR
Date: 2026.08.13 16:41:01
+05'30'

Nikhilkumar Yashvntlal Thakkar
Managing Director
DIN: 07962800

Encl.: As Above



This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCIENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifescience.com; **Tel No:** +91 99250 58245/43; **Email Id:** info@sunrestlifescience.com; **Contact person:** Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

*Assuming full subscription and receipt of all Call Monies with respect to Rights Equity Shares.

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED

ISSUE OPENS ON	LAST DATE FOR ON MARKET RENUNCIATION*	ISSUE CLOSSES ON#
TUESDAY AUGUST 18, 2026	FRIDAY AUGUST 28, 2026	WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

**Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.*

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*

*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INE0PLZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSSB or online/electronic Application through the website of the SCSSBs (if made available by such SCSSB) for authorising such SCSSB to block Application Money payable on the Application in their respective ASBA Accounts.

Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedPF=yes&intmid=35>. For details on Designated Branches of SCSSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process:

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSSB for authorising such SCSSB to block Application Money in the said bank account maintained with the same SCSSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCIENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No;
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares entitled to;
- Number of Rights Equity Shares applied for within the Rights Entitlements;
- Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Rights Equity Shares applied for;
- Total amount paid at the rate of Rs.35/- per Rights Equity Share;
- Details of the ASBA Account such as the SCSSB account number, name, address and branch of the relevant SCSSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:
"I/ We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/ we understand the Rights Equity Shares referred to in this application are being offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/ we understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/ we confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.
I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/ We satisfy, and each account for which I/ we are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.
I/ we hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.
I/ We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinereta.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlement in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER INTO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only In Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e. Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (IN ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEIL (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEIL") should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by NSEIL, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" on page 94 of the Letter of Offer.

Banker To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e. Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifescience.com;
- the Registrar to the Issue at www.skylinereta.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinereta.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out to the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors:
<https://www.skylinereta.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company:
www.skylinereta.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinereta.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase – I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id ipo@skylinereta.com.

COMPANY DETAILS
SUNREST LIFESCIENCE LIMITED CIN: L74999GJ2017PLC099606 Registered Office: D-608, West Gate, Nr. Brooklin Tower, YMCA Club, Nr. S G Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India; Tel. No.: +91 99250 58245/43; Email: info@sunrestlifescience.com Website: www.sunrestlifescience.com Contact Person: Nabil Ansari, Company Secretary & Compliance Officer
REGISTRAR TO THE ISSUE
SKYLINE FINANCIAL SERVICES PRIVATE LIMITED D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020 Tel: +91-11-4045 0193-97 Email: ipo@skylinereta.Com Website: www.skylinereta.com Investors Grievance E-mail: grievances@skylinereta.com Contact Person: Mr. Anuj Rana SEBI Registration Number: INR000003241

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

Date: August 12, 2026 PLACE: Ahmedabad	For, Sunrest Lifescience Limited Sd/- Nikhilkumar Y Thakkar Managing Director Din:07662800
---	---

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEIL at www.nseindia.com and, Company at www.sunrestlifescience.com, website of the Registrar to the Issue at www.skylinereta.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any Investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

TAI INDUSTRIES LIMITED					
CIN: L01222WB1983PLC059695					
Registered Office : Arihant Building, 3rd Floor, 53A, Mirza Ghalib Street, Kolkata - 700 016					
Phone No. : (033) 4041 6666					
E-mail : info@taiind.com, Website : www.taiind.com					
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026					
					(₹ in Lakhs)
Sl. No.	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
1	Total Income from Operations	3,578.59	6,164.57	2,549.04	15,966.57
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	(43.21)	4.70	1.08	25.69
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	(43.21)	4.70	1.08	25.69
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	(43.21)	4.29	0.10	9.55
5	Total Comprehensive income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(41.68)	(53.31)	27.75	(43.10)
6	Paid up Equity Share Capital (₹ 10/- each)	600.00	600.00	600.00	600.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2,360.51
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) -				
	1. Basic (₹)	(0.72)	0.07	0.00	0.16
	2. Diluted (₹)	(0.72)	0.07	0.00	0.16
Note :					
a) The above is an extract of the detailed format of Quarterly/ Year ended Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the website of the Stock Exchange at www.bseindia.com and also on the website of the Company, at www.taiind.com					
			For Tai Industries Limited Rohan Ghosh (Managing Director) (DIN - 00032965)		
Place : Kolkata					
Date : 12th August, 2026					



Alivus Life Sciences Limited

(formerly Glenmark Life Sciences Limited)

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeh, Solapur 413 213, India.

Corporate Office: Technopolis Knowledge Park, A Wing, Office no. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093

Phone No.: +91 22 68297979; **CIN:** L74900PN2011PLC139963; **Website:** www.alivus.com **Email:** complianceofficer@alivus.com

NOTICE

NOTICE is hereby given that the **15th Annual General Meeting (AGM)** of the Members of the Company will be held on **Tuesday, September 8, 2026 at 3.00 p.m. (IST)** through two-way Video Conferencing (VC)/Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (together referred to as "Circulars").

The Notice setting out the Ordinary and Special business(es) to be transacted during the AGM and the Integrated Annual Report 2025-26 (Annual Report) has been sent by email to the members whose email IDs are registered with the Depository Participant (DP) or the Company. The email dispatch has been completed on August 11, 2026. Further the Company is sending a letter providing the web-link where complete details of the Annual Report is available, to those members who have not registered their email IDs.

The Notice of the AGM and the Annual Report are available on the website of the Company, i.e. www.alivus.com and on the websites of the stock exchanges, i.e. www.bseindia.com and www.nseindia.com. The Notice of the AGM is also available on the website of NSDL i.e. www.evoting.nsdl.com. The Annual Report can also be accessed by scanning the QR code.

In terms of the provisions of Section 108 and other applicable provisions, if any, of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended, and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is pleased to provide to its members the facility to exercise their right to vote on the resolutions proposed to be passed during the AGM by electronic means. The Company has appointed National Securities Depositories Limited (NSDL) as the agency to provide electronic voting facility. Members holding shares as on the cut-off date may cast their votes using an electronic voting system (remote e-voting). All members may please note the following:

Cut-Off Date	Tuesday, September 01, 2026
Commencement of Remote e-voting	Friday, September 04, 2026 (From 9.00 a.m. IST)
End of Remote e-voting	Monday, September 07, 2026 (Up to 5:00 p.m. IST)

Remote e-voting will be disabled by NSDL upon expiry of the aforesaid period.

The facility for voting through the e-voting system will also be made available during the AGM. Members attending the AGM through VC facility who have not cast their vote by remote e-voting will be able to vote during the AGM.

Members who have cast their vote by remote e-voting may also attend the AGM but will not be entitled to cast their vote again. Once the vote on a resolution is cast by a member, the member will not be allowed to change it subsequently or cast the vote again.

Only a person whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date shall be entitled to avail of the remote e-voting facility. Voting rights shall be reckoned on the paid-up value of shares registered in the name of the member / beneficial owner (in case of electronic shareholding) as on the cut-off date.

The manner of voting remotely for members holding shares in dematerialised and physical modes as well as for members who have not registered their email IDs is provided in the Notice of the AGM (refer Serial No. 34 of the Notes). Any person who becomes a member of the Company after email dispatch of the Notice of the AGM and holding shares as on the cut-off date may obtain the user ID and password by sending an email request to evoting@nsdl.co.in. However, if a person is already registered with NSDL for e-voting, then his existing user ID and password can be used for casting the vote.

Queries	Manner of registering / updating email IDs
Members who need assistance before or during the AGM, can contact NSDL on evoting@nsdl.co.in or call at : 022-48867000	- To support the green initiative and to receive communications from the Company in electronic mode, members who have not registered their email ID so far are requested to register the same with their DP, if shares are held in demat form. - Members holding shares in physical mode, who have not registered/ updated their email address with the Company are requested to register/ update their email addresses by submitting requisite documents to KFin at Selenium Tower B, Plot No. 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad 500032.

By Order of the Board
For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)
Sd/-
Rudalf Corriea
Company Secretary & Compliance Officer

Place : Mumbai
Date : August 12, 2026

Ahmedabad



This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCIENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifescience.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifescience.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS" ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

* Assuming full subscription and receipt of all Call Monies with respect to Rights Equity Shares.

ISSUE OPENS ON
TUESDAY AUGUST 18, 2026

LAST DATE FOR ON MARKET RENUNCIATION*
FRIDAY AUGUST 28, 2026

ISSUE CLOSES ON#
WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*

*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INEP0LZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCIENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares entitled to;
- Number of Rights Equity Shares applied for within the Rights Entitlements;
- Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Rights Equity Shares applied for;
- Total amount paid at the rate of Rs.35/- per Rights Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:

"I/ We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/ we understand the Rights Equity Shares referred to in this application are being offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/ we understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/ we confirm that I/ am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/ We satisfy, and each account for which I/ we are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction or residence.

I/ we hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.

I/ We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinert.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlement in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER INTO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only in Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e., Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEIL (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEIL") should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by NSEIL, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" on page 94 of the Letter of Offer.

Banker To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e., Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifescience.com;
- the Registrar to the Issue at www.skylinert.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinert.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: <https://www.skylinert.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: www.skylinert.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinert.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase -I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id atipo@skylinert.com.



COMPANY DETAILS

SUNREST LIFESCIENCE LIMITED

CIN: L74999GJ2017PLC099606

Registered Office: D-608, West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India ; Tel. No.: +91 99250 58245/43;

Email: info@sunrestlifescience.com Website: www.sunrestlifescience.com

Contact Person: Nabil Ansari, Company Secretary & Compliance Officer



REGISTRAR TO THE ISSUE

SKYLINE FINANCIAL SERVICES PRIVATE LIMITED

D-153/A, First Floor, Okhla Industrial Area, Phase -I, New Delhi – 110020

Tel: +91-11-4045 0193-97 Email: ipo@skylinert.com Website: www.skylinert.com

Investors Grievance E-mail: grievances@skylinert.com Contact Person: Mr. Anuj Rana

SEBI Registration Number: INR00003241

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

For, Sunrest Lifescience Limited
Sd/-
Nikhilkumar Y Thakkar
Managing Director
Din: 07662800

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEIL at www.nseindia.com and, Company at www.sunrestlifescience.com, website of the Registrar to the Issue at www.skylinert.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

TAI INDUSTRIES LIMITED					
CIN: L01222WB1983PLC059695					
Registered Office : Arihant Building, 3rd Floor, 53A, Mirza Ghalib Street, Kolkata - 700 016					
Phone No. : (033) 4041 6666					
E-mail : info@taiind.com Website : www.taiind.com					
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026					
(₹ in Lakhs)					
Sl. No.	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
1	Total Income from Operations	3,578.59	6,164.57	2,549.04	15,966.57
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(43.21)	4.70	1.08	25.89
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.70	1.08	25.89
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.29	0.10	9.55
5	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(41.68)	(53.31)	27.75	(43.10)
6	Paid up Equity Share Capital (₹ 10/- each)	600.00	600.00	600.00	600.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2,360.51
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) -				
1. Basic (₹)	(0.72)	0.07	0.00	0.16	
2. Diluted (₹)	(0.72)	0.07	0.00	0.16	
Note :					
a) The above is an extract of the detailed format of Quarterly/ Year ended Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the website of the Stock Exchange at www.bseindia.com and also on the website of the Company, at www.taiind.com					
For Tai Industries Limited Rohan Ghosh (Managing Director) (DIN - 00032965)					
Place : Kolkata Date : 12th August, 2026					



Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur 413 213, India.

Corporate Office: Technopolis Knowledge Park, A Wing, Office no. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093

Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963

Website: www.alivus.com Email: complianceofficer@alivus.com

NOTICE

NOTICE is hereby given that the **15th Annual General Meeting (AGM)** of the Members of the Company will be held on **Tuesday, September 8, 2026 at 3.00 p.m. (IST)** through two-way Video Conferencing (VC)/Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (together referred to as "Circulars").

The Notice setting out the Ordinary and Special business(es) to be transacted during the AGM and the Integrated Annual Report 2025-26 (Annual Report) has been sent by email to the members whose email IDs are registered with the Depository Participant (DP) or the Company. The email dispatch has been completed on August 11, 2026. Further the Company is sending a letter providing the web-link where complete details of the Annual Report is available, to those members who have not registered their email IDs.

The Notice of the AGM and the Annual Report are available on the website of the Company, i.e., www.alivus.com and on the websites of the stock exchanges, i.e., www.bseindia.com and www.nseindia.com. The Notice of the AGM is also available on the website of NSDL i.e. www.evoting.nsdl.com. The Annual Report can also be accessed by



This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCIENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklyn Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifescience.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifescience.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

* Assuming full subscription and receipt of all Call Monies with respect to Rights Equity Shares.

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED

ISSUE OPENS ON
TUESDAY AUGUST 18, 2026

LAST DATE FOR ON MARKET RENUNCIATION*
FRIDAY AUGUST 28, 2026

ISSUE CLOSING ON#
WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to be credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA* Simple, Safe, Smart way of making an application - Make use of it
*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INE0PLZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedPip=yes&intmid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCIENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares entitled to;
- Number of Rights Equity Shares applied for within the Rights Entitlements;
- Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Rights Equity Shares applied for;
- Total amount paid at the rate of Rs.35/- per Rights Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:

"I/ We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/ we understand the Rights Equity Shares referred to in this application are being offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/ we understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements in the United States. I/ we confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/ We satisfy, and each account for which I/ we are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/ we hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.

I/ We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinert.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlement in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER TO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked in an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only In Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (6) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e., Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEI (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEI") should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by NSEI, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSEI" on page 94 of the Letter of Offer.

Banker To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispensed only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e. Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifescience.com;
- the Registrar to the Issue at www.skylinert.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinert.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors:
<https://www.skylinert.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company:
www.skylinert.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinert.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id ipo@skylinert.com.

COMPANY DETAILS	
SUNREST LIFESCIENCE LIMITED CIN: L74999GJ2017PLC099606 Registered Office: D-608, West Gate, Nr. Brooklyn Tower, YMCA Club, Nr. S G Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India ; Tel. No.: +91 99250 58245/43; Email: info@sunrestlifescience.com Website: www.sunrestlifescience.com Contact Person: Nabil Ansari, Company Secretary & Compliance Officer	
REGISTRAR TO THE ISSUE	
SKYLINE FINANCIAL SERVICES PRIVATE LIMITED D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020 Tel: +91-11-4045 0193-97 Email: ipo@skylinert.com Website: www.skylinert.com Investors Grievance E-mail: grievances@skylinert.com Contact Person: Mr. Anuj Rana SEBI Registration Number: INR000003241	

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

For, Sunrest Lifescience Limited
Sd/-
Nikhilkumar Y Thakkar
Managing Director
Din:07662800

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEI, at www.nseindia.com and, Company at www.sunrestlifescience.com, website of the Registrar to the Issue at www.skylinert.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

TAI INDUSTRIES LIMITED					
CIN: L01222WB1983PLC059695					
Registered Office : Arianth Building, 3rd Floor, 53A, Mirza Ghalib Street, Kolkata - 700 016					
Phone No. : (033) 4041 6666					
E-mail : info@taiind.com Website : www.taiind.com					
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026					
Sl. No.	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
1	Total Income from Operations	3,578.59	6,164.57	2,549.04	15,966.57
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(43.21)	4.70	1.08	25.89
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.70	1.08	25.89
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.29	0.10	9.35
5	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(41.88)	(53.31)	27.75	(43.10)
6	Paid up Equity Share Capital (₹ 10/- each)	600.00	600.00	600.00	600.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2,360.51
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) - 1. Basic (₹) 2. Diluted (₹)	(0.72) (0.72)	0.07 0.07	0.00 0.00	0.16 0.16
Note : a) The above is an extract of the detailed format of Quarterly/ Year ended Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the website of the Stock Exchange at www.bseindia.com and also on the website of the Company, at www.taiind.com					
For Tai Industries Limited Rohan Ghosh (Managing Director) (DIN - 00032965)					
Place : Kolkata Date : 12th August, 2026					



Alivus Life Sciences Limited

(formerly Glenmark Life Sciences Limited)

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpethi, Solapur 413 213, India.

Corporate Office: Technopolis Knowledge Park, A Wing, Office no. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093

Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963; Website: www.alivus.com Email: complianceofficer@alivus.com

NOTICE

NOTICE is hereby given that the **15th Annual General Meeting (AGM)** of the Members of the Company will be held on **Tuesday, September 8, 2026 at 3.00 p.m. (IST)** through two-way Video Conferencing (VC)/Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (together referred to as "Circulars").

The Notice setting out the Ordinary and Special business(es) to be transacted during the AGM and the Integrated Annual Report 2025-26 (Annual Report) has been sent by email to the members whose email IDs are registered with the Depository Participant (DP) or the Company. The email dispatch has been completed on August 11, 2026. Further the Company is sending a letter providing the web-link where complete details of the Annual Report is available, to those members who have not registered their email IDs.

The Notice of the AGM and the Annual Report are available on the website of the Company, i.e. www.alivus.com and on the websites of the stock exchanges, i.e. www.bseindia.com and



This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCIENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifescience.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifescience.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS" ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

* Assuming full subscription and receipt of all Monies with respect to Rights Equity Shares.

ISSUE OPENS ON
TUESDAY AUGUST 18, 2026

LAST DATE FOR ON MARKET RENUNCIATION*
FRIDAY AUGUST 28, 2026

ISSUE CLOSES ON#
WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*

*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INEP0LZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCIENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares entitled to;
- Number of Rights Equity Shares applied for within the Rights Entitlements;
- Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Rights Equity Shares applied for;
- Total amount paid at the rate of Rs.35/- per Rights Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:

"I/ We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/ we understand the Rights Equity Shares referred to in this application are being offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/ we understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/ we confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/ We satisfy, and each account for which I/ we are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/ we hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.

I/ We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinert.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlement in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER INTO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only in Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e., Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEI (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEI") should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by NSEI, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSEI" on page 94 of the Letter of Offer.

Banker To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e., Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifescience.com;
- the Registrar to the Issue at www.skylinert.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinert.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: <https://www.skylinert.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: www.skylinert.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinert.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id atipo@skylinert.com.



COMPANY DETAILS

SUNREST LIFESCIENCE LIMITED

CIN: L74999GJ2017PLC099606

Registered Office: D-608, West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India ; Tel. No.: +91 99250 58245/43; Email: info@sunrestlifescience.com Website: www.sunrestlifescience.com Contact Person: Nabil Ansari, Company Secretary & Compliance Officer



REGISTRAR TO THE ISSUE

SKYLINE FINANCIAL SERVICES PRIVATE LIMITED

D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020

Tel: +91-11-4045 0193-97 Email: ipo@skylinert.com Website: www.skylinert.com

Investors Grievance E-mail: grievances@skylinert.com Contact Person: Mr. Anuj Rana

SEBI Registration Number: INR00003241

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

For, Sunrest Lifescience Limited
Sd/-
Nikhilkumar Y Thakkar
Managing Director
Din: 07662800

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEI, at www.nseindia.com and, Company at www.sunrestlifescience.com, website of the Registrar to the Issue at www.skylinert.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

TAI INDUSTRIES LIMITED					
CIN: L01222WB1983PLC059695					
Registered Office : Arihant Building, 3rd Floor, 53A, Mirza Ghalib Street, Kolkata - 700 016					
Phone No. : (033) 4041 6666					
E-mail : info@taiind.com Website : www.taiind.com					
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026					
(₹ in Lakhs)					
Sl. No.	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
1	Total Income from Operations	3,578.59	6,164.57	2,549.04	15,966.57
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(43.21)	4.70	1.08	25.89
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.70	1.08	25.89
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.29	0.10	9.55
5	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(41.68)	(53.31)	27.75	(43.10)
6	Paid up Equity Share Capital (₹ 10/- each)	600.00	600.00	600.00	600.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2,360.51
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) - 1. Basic (₹) 2. Diluted (₹)	(0.72) (0.72)	0.07 0.07	0.00 0.00	0.16 0.16
Note : a) The above is an extract of the detailed format of Quarterly/ Year ended Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the website of the Stock Exchange at www.bseindia.com and also on the website of the Company, at www.taiind.com					
For Tai Industries Limited Rohan Ghosh (Managing Director) (DIN - 00032965)					
Place : Kolkata Date : 12th August, 2026					



Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur 413 213, India.

Corporate Office: Technopolis Knowledge Park, A Wing, Office no. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093

Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963

Website: www.alivus.com Email: complianceofficer@alivus.com

NOTICE

NOTICE is hereby given that the **15th Annual General Meeting (AGM)** of the Members of the Company will be held on **Tuesday, September 8, 2026 at 3.00 p.m. (IST)** through two-way Video Conferencing (VC)/Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (together referred to as "Circulars").

The Notice setting out the Ordinary and Special business(es) to be transacted during the AGM and the Integrated Annual Report 2025-26 (Annual Report) has been sent by email to the members whose email IDs are registered with the Depository Participant (DP) or the Company. The email dispatch has been completed on August 11, 2026. Further the Company is sending a letter providing the web-link where complete details of the Annual Report is available, to those members who have not registered their email IDs.

The Notice of the AGM and the Annual Report are available on the website of the Company, i.e., www.alivus.com and on the websites of the stock exchanges, i.e., www.bseindia.com and www.nseindia.com. The Notice of the AGM is also available on the website of NSDL i.e. www.evoting.nsdl.com. The Annual Report can also be accessed by scanning the QR code.

In terms of the provisions of Section 108 and other applicable provisions, if any, of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended, and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations



This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCIENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifescience.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifescience.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS" ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

* Assuming full subscription and receipt of all Monies with respect to Rights Equity Shares.

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED

ISSUE OPENS ON

TUESDAY AUGUST 18, 2026

LAST DATE FOR ON MARKET RENUNCIATION*

FRIDAY AUGUST 28, 2026

ISSUE CLOSING ON#

WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*

*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INEP0LZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCIENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares entitled to;
- Number of Rights Equity Shares applied for within the Rights Entitlements;
- Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Rights Equity Shares applied for;
- Total amount paid at the rate of Rs.35/- per Rights Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:

"I/We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/We understand the Rights Equity Shares referred to in this application are being offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/We understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/We confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/We satisfy, and each account for which I/We are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction or residence.

I/We hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.

I/We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinert.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date.

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlement in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER INTO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only in Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e., Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEIL (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEIL") should not in any way, be deemed or construed that the Letter of Offer has been cleared or approved by NSEIL, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" on page 94 of the Letter of Offer.

Banker To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e., Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifescience.com;
- the Registrar to the Issue at www.skylinert.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinert.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: <https://www.skylinert.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: www.skylinert.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinert.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id atipo@skylinert.com.



COMPANY DETAILS

SUNREST LIFESCIENCE LIMITED

CIN: L74999GJ2017PLC099606

Registered Office: D-608, West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India ; Tel. No.: +91 99250 58245/43; Email: info@sunrestlifescience.com Website: www.sunrestlifescience.com Contact Person: Nabil Ansari, Company Secretary & Compliance Officer



REGISTRAR TO THE ISSUE

SKYLINE FINANCIAL SERVICES PRIVATE LIMITED

D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020

Tel: +91-11-4045 0193-97 Email: ipo@skylinert.com Website: www.skylinert.com

Investors Grievance E-mail: grievances@skylinert.com Contact Person: Mr. Anuj Rana

SEBI Registration Number: INR00003241

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

For, Sunrest Lifescience Limited
Sd/-
Nikhilkumar Y Thakkar
Managing Director
Din: 07662800

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEIL at www.nseindia.com and, Company at www.sunrestlifescience.com, website of the Registrar to the Issue at www.skylinert.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

TAI INDUSTRIES LIMITED					
CIN: L01222WB1983PLC059695					
Registered Office : Arihant Building, 3rd Floor, 53A, Mirza Ghalib Street, Kolkata - 700 016					
Phone No. : (033) 4041 6666					
E-mail : info@taiind.com Website : www.taiind.com					
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026					
(₹ in Lakhs)					
Sl. No.	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
1	Total Income from Operations	3,578.59	6,164.57	2,549.04	15,966.57
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(43.21)	4.70	1.08	25.89
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.70	1.08	25.89
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.29	0.10	9.55
5	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(41.68)	(53.31)	27.75	(43.10)
6	Paid up Equity Share Capital (₹ 10/- each)	600.00	600.00	600.00	600.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2,360.51
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) -				
1. Basic (₹)	(0.72)	0.07	0.00	0.16	
2. Diluted (₹)	(0.72)	0.07	0.00	0.16	
Note :					
a) The above is an extract of the detailed format of Quarterly/ Year ended Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the website of the Stock Exchange at www.bseindia.com and also on the website of the Company, at www.taiind.com					
For Tai Industries Limited Rohan Ghosh (Managing Director) (DIN - 00032965)					
Place : Kolkata Date : 12th August, 2026					



Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpet, Solapur 413 213, India.

Corporate Office: Technopolis Knowledge Park, A Wing, Office no. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093

Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963

Website: www.alivus.com Email: complianceofficer@alivus.com

NOTICE

NOTICE is hereby given that the 15th Annual General Meeting (AGM) of the Members of the Company will be held on **Tuesday, September 8, 2026 at 3.00 p.m. (IST)** through two-way Video Conferencing (VC)/Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (together referred to as "Circulars").

The Notice setting out the Ordinary and Special business(es) to be transacted during the AGM and the Integrated Annual Report 2025-26 (Annual Report) has been sent by email to the members whose email IDs are registered with the Depository Participant (DP) or the Company. The email dispatch has been completed on August 11, 2026. Further the Company is sending a letter providing the web-link where complete details of the Annual Report is available, to those members who have not registered their email IDs.

The Notice of the AGM and the Annual Report are available on the website of the Company, i.e., www.alivus.com and on the websites of the stock exchanges, i.e., www.bseindia.com and www.nseindia.com. The Notice of the AGM is also available on the website of



This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCIENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifescience.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifescience.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR Y THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

* Assuming full subscription and receipt of all Call Monies with respect to Rights Equity Shares.

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED

ISSUE OPENS ON

TUESDAY AUGUST 18, 2026

LAST DATE FOR ON MARKET RENUNCIATION*

FRIDAY AUGUST 28, 2026

ISSUE CLOSSES ON#

WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*

Simple, Safe, Smart way of making an application - Make use of it

*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INEP0PLZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by the Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

SCSBs should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation in the Issue, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&ntmlid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCIENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares applied for;
- Number of Rights Equity Shares entitled to within the Rights Entitlements;
- Number of Rights Equity Shares applied for; if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Additional Rights Equity Shares applied for;
- Total amount paid at the rate of Rs. 35/- per Rights Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:

"I/We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred from, in the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/We understand the Rights Equity Shares referred to in this regulation are to be offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/We understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation thereof of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/We confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction, or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/We satisfy, and each account for which I/We are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence. I/We hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.

I/We acknowledge that the Company, its affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements.

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinereta.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date.

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlements Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlements Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlements Letter only to Eligible Equity Shareholders who have provided an Indian address under our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, in the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlement in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER INTO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only In Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e., Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as their intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEIL (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEIL") should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by NSEIL, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" on page 94 of the Letter of Offer.

Banking To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispatched only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e., Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifescience.com;
- the Registrar to the Issue at www.skylinereta.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinereta.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: <https://www.skylinereta.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: www.skylinereta.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinereta.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase-I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id atjpo@skylinereta.com.



SUNREST LIFESCIENCE LIMITED
CIN: L74999GJ2017PLC099606

Registered Office: D-608, West Gate, Nr. Brooklin Tower, YMCA Club, Nr. S G Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India ; Tel. No: +91 99250 58245/43; Email: info@sunrestlifescience.com Website: www.sunrestlifescience.com Contact Person: Nabil Ansari, Company Secretary & Compliance Officer



SKYLINE FINANCIAL SERVICES PRIVATE LIMITED
D-153/A, First Floor, Okhla Industrial Area, Phase-I, New Delhi – 110020
Tel: +91-11-4045 0193-97 Email: ipo@skylinereta.com Website: www.skylinereta.com
Investors Grievance E-mail: grievances@skylinereta.com Contact Person: Mr. Anuj Rana
SEBI Registration Number: INR000003241

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

For, Sunrest Lifescience Limited
Nikhil Kumar Y Thakkar
Managing Director
Din: 07662800

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., nseindia.com and, Company.atwww.sunrestlifescience.com, website of the Registrar to the Issue at www.skylinereta.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

TAI INDUSTRIES LIMITED					
CIN: L0122WB1983PLC059695					
Registered Office : Arianth Building, 3rd Floor, 53A, Mirza Ghalib Street, Kolkata - 700 016					
Phone No. : (033) 4041 6666					
E-mail : info@taiind.com ; Website : www.taiind.com					
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026					
(₹ in Lakhs)					
Sl. No.	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
1	Total Income from Operations	3,578.59	6,164.57	2,549.04	15,966.57
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(43.21)	4.70	1.08	25.89
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.70	1.08	25.89
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.29	0.10	9.5
5	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(41.68)	(53.31)	27.75	(43.10)
6	Paid up Equity Share Capital (₹ 10/- each)	600.00	600.00	600.00	600.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2,360.51
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) -				
	1. Basic (₹)	(0.72)	0.07	0.00	0.16
	2. Diluted (₹)	(0.72)	0.07	0.00	0.16

Note : a) The above is an extract of the detailed format of Quarterly/ Year ended Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the website of the Stock Exchange, at www.bseindia.com and also on the website of the Company, at www.taiind.com.

For Tai Industries Limited
Rohan Ghosh
(Managing Director)
(DIN - 00032965)

Place : Kolkata
Date : 12th August, 2026



Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeeth, Solapur 413 213, India.

Corporate Office: Technopolis Knowledge Park, A Wing, Office no. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093
Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963;
Website: www.alivus.com Email: complianceofficer@alivus.com

NOTICE

NOTICE is hereby given that the 15th Annual General Meeting (AGM) of the Members of the Company will be held on **Tuesday, September 8, 2026 at 3.00 p.m. (IST)** through two-way Video Conferencing (VC)/Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (together referred to as 'Circulars').

The Notice setting out the Ordinary and Special business(es) to be transacted during the AGM and the Integrated Annual Report 2025-26 (Annual Report) has been sent by email to the members whose email IDs are registered with the Depository Participant (DP) or the Company. The email dispatch has been completed on August 11, 2026. Further the Company is sending a letter providing the web-link where complete details of the Annual Report is available, to those members who have not registered their email IDs.

The Notice of the AGM and the Annual Report are available on the website of the Company, i.e. www.alivus.com and on the websites of the stock exchanges, i.e. www.bseindia.com and www.nseindia.com.



This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCIENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklyn Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifescience.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifescience.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

* Assuming full subscription and receipt of all Call Monies with respect to Rights Equity Shares.

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED

ISSUE OPENS ON
TUESDAY AUGUST 18, 2026

LAST DATE FOR ON MARKET RENUNCIATION*
FRIDAY AUGUST 28, 2026

ISSUE CLOSES ON#
WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA* Simple, Safe, Smart way of making an application - Make use of it
*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INEQPLZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedPip=yes&intmid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCIENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares entitled to;
- Number of Rights Equity Shares applied for within the Rights Entitlements;
- Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Rights Equity Shares entitled to;
- Total amount paid at the rate of Rs.35/- per Rights Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:

"I/ We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/ We understand the Rights Equity Shares referred to in this application are being offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/ We understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/ We confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/ We satisfy, and each account for which I/ We are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/ We hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.

I/ We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinert.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlement in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER TO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked in an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only In Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (6) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e., Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEI (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEI") should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by NSEI, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSEI" on page 94 of the Letter of Offer.

Banker To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e. Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifescience.com;
- the Registrar to the Issue at www.skylinert.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinert.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors:
<https://www.skylinert.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company:
www.skylinert.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinert.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id ipo@skylinert.com.

COMPANY DETAILS	
SUNREST LIFESCIENCE LIMITED CIN: L74999GJ2017PLC099606 Registered Office: D-608, West Gate, Nr. Brooklyn Tower, YMCA Club, Nr. S G Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India ; Tel. No.: +91 99250 58245/43; Email: info@sunrestlifescience.com Website: www.sunrestlifescience.com Contact Person: Nabil Ansari, Company Secretary & Compliance Officer	
REGISTRAR TO THE ISSUE	
SKYLINE FINANCIAL SERVICES PRIVATE LIMITED D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020 Tel: +91-11-4045 0193-97 Email: ipo@skylinert.com Website: www.skylinert.com Investors Grievance E-mail: grievances@skylinert.com Contact Person: Mr. Anuj Rana SEBI Registration Number: INR000003241	

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

For, Sunrest Lifescience Limited
Sd/-
Nikhilkumar Y Thakkar
Managing Director
Din:07662800

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEI, at www.nseindia.com and, Company at www.sunrestlifescience.com, website of the Registrar to the Issue at www.skylinert.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

TAI INDUSTRIES LIMITED					
CIN: L0122WB1983PLC059695					
Registered Office : Arianth Building, 3rd Floor, 53A, Mirza Ghalib Street, Kolkata - 700 016					
Phone No. : (033) 4041 6666					
E-mail : info@taiind.com Website : www.taiind.com					
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026					
Sl. No.	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
1	Total Income from Operations	3,578.59	6,164.57	2,549.04	15,966.57
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	(43.21)	4.70	1.08	25.89
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items#)	(43.21)	4.70	1.08	25.89
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items#)	(43.21)	4.29	0.10	9.55
5	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(41.68)	(53.31)	27.75	(43.10)
6	Paid up Equity Share Capital (₹ 10/- each)	600.00	600.00	600.00	600.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2,360.51
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) - 1. Basic (₹) 2. Diluted (₹)	(0.72) (0.72)	0.07 0.07	0.00 0.00	0.16 0.16
Note : a) The above is an extract of the detailed format of Quarterly/ Year ended Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the website of the Stock Exchange at www.bseindia.com and also on the website of the Company, at www.taiind.com					
For Tai Industries Limited Rohan Ghosh (Managing Director) (DIN - 00032965)					
Place : Kolkata Date : 12th August, 2026					

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)	
Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeti, Solapur 413 213, India.	
Corporate Office: Technopolis Knowledge Park, A Wing, Office no. 401 to 407, 4 th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093	
Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963; Website: www.alivus.com Email: complianceofficer@alivus.com	

NOTICE

NOTICE is hereby given that the **15th Annual General Meeting (AGM)** of the Members of the Company will be held on **Tuesday, September 8, 2026 at 3.00 p.m. (IST)** through two-way Video Conferencing (VC)/Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (together referred to as "Circulars").

The Notice setting out the Ordinary and Special business(es) to be transacted during the AGM and the Integrated Annual Report 2025-26 (Annual Report) has been sent by email to the members whose email IDs are registered with the Depository Participant (DP) or the Company. The email dispatch has been completed on August 11, 2026. Further the Company is sending a letter providing the web-link where complete details of the Annual Report is available, to those members who have not registered their email IDs.

This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifesceince.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifesceince.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS" ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

* Assuming full subscription and receipt of all Monies with respect to Rights Equity Shares.

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCENCE LIMITED

ISSUE OPENS ON	LAST DATE FOR ON MARKET RENUNCIATION*	ISSUE CLOSING ON#
TUESDAY AUGUST 18, 2026	FRIDAY AUGUST 28, 2026	WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*

*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INE0PLZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescence Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares entitled to;
- Number of Rights Equity Shares applied for within the Rights Entitlements;
- Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Rights Equity Shares applied for;
- Total amount paid at the rate of Rs.35/- per Rights Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:

"I/ We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/ We understand the Rights Equity Shares referred to in this application are being offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/ We understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/ We confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/ We satisfy, and each account for which I/ We are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/ We hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.

I/ We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinert.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date.

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlements in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER INTO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only in Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescence Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (6) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e. Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEIL (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEIL") should not in any way, be deemed or construed that the Letter of Offer has been cleared or approved by NSEIL, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" on page 94 of the Letter of Offer.

Banker To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e. Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifesceince.com;
- the Registrar to the Issue at www.skylinert.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinert.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: <https://www.skylinert.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: www.skylinert.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinert.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id atipo@skylinert.com.

COMPANY DETAILS
SUNREST LIFESCENCE LIMITED CIN: L74999GJ2017PLC099606 Registered Office: D-608, West Gate, Nr. Brooklin Tower, YMCA Club, Nr. S G Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India ; Tel. No.: +91 99250 58245/43; Email: info@sunrestlifesceince.com Website: www.sunrestlifesceince.com Contact Person: Nabil Ansari, Company Secretary & Compliance Officer

REGISTRAR TO THE ISSUE
SKYLINE FINANCIAL SERVICES PRIVATE LIMITED D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020 Tel: +91-11-4045 0193-97 Email: ipo@skylinert.com Website: www.skylinert.com Investors Grievance E-mail: grievances@skylinert.com Contact Person: Mr. Anuj Rana SEBI Registration Number: INR00003241

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

For, Sunrest Lifescence Limited
 Sd/-
 Nikhilkumar Y Thakkar
 Managing Director
 Din: 07662800

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEIL at www.nseindia.com and, Company at www.sunrestlifesceince.com, website of the Registrar to the Issue at www.skylinert.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

TAI INDUSTRIES LIMITED					
CIN: L01222WB1983PLC056995					
Registered Office : Arihant Building, 3rd Floor, 53A, Mirza Ghalib Street, Kolkata - 700 016					
Phone No. : (033) 4041 6666					
E-mail : info@taiind.com Website : www.taiind.com					
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026					
₹ (in Lakhs)					
Sl. No.	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
1	Total Income from Operations	3,578.59	6,164.57	2,549.04	15,966.57
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(43.21)	4.70	1.08	25.89
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.70	1.08	25.89
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.29	0.10	9.55
5	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(41.68)	(53.31)	27.75	(43.10)
6	Paid up Equity Share Capital (₹ 10/- each)	600.00	600.00	600.00	600.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2,360.51
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) -				
1. Basic (₹)		(0.72)	0.07	0.00	0.16
2. Diluted (₹)		(0.72)	0.07	0.00	0.16

Note : a) The above is an extract of the detailed format of Quarterly/ Year ended Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the website of the Stock Exchange at www.bseindia.com and also on the website of the Company, at www.taiind.com.

For Tai Industries Limited
 Rohan Ghosh
 (Managing Director)
 (DIN - 00032965)

Place : Kolkata
 Date : 12th August, 2026

ALIVUS
 LIFE SCIENCES
 Live every day

Alivus Life Sciences Limited
 (formerly Glenmark Life Sciences Limited)

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpet, Solapur 413 213, India.

Corporate Office: Technopolis Knowledge Park, A Wing, Office no. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093

Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963

Website: www.alivus.com; Email: complianceofficer@alivus.com

NOTICE

NOTICE is hereby given that the **15th Annual General Meeting (AGM)** of the Members of the Company will be held on **Tuesday, September 8, 2026 at 3.00 p.m. (IST)** through two-way Video Conferencing (VC)/Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (together referred to as "Circulars").

The Notice setting out the Ordinary and Special business(es) to be transacted during the AGM and the Integrated Annual Report 2025-26 (Annual Report) has been sent by email to the members whose email IDs are registered with the Depository Participant (DP) or the Company. The email dispatch has been completed on August 11, 2026. Further the Company is sending a letter providing the web-link where complete details of the Annual Report is available, to those members who have not registered their email IDs.



This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCIENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifesceince.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifesceince.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS" ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

* Assuming full subscription and receipt of all Monies with respect to Rights Equity Shares.

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED

ISSUE OPENS ON TUESDAY AUGUST 18, 2026	LAST DATE FOR ON MARKET RENUNCIATION* FRIDAY AUGUST 28, 2026	ISSUE CLOSSES ON# WEDNESDAY SEPTEMBER 02, 2026
--	--	--

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*

*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INEP0LZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCIENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares entitled to;
- Number of Rights Equity Shares applied for within the Rights Entitlements;
- Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Rights Equity Shares applied for;
- Total amount paid at the rate of Rs.35/- per Rights Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:

"I/ We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/ we understand the Rights Equity Shares referred to in this application are being offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/ we understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/ we confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/ We satisfy, and each account for which I/ we are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/ we hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.

I/ We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinert.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlement in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER INTO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only in Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e., Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEIL (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEIL") should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by NSEIL, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" on page 94 of the Letter of Offer.

Banker To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e., Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifesceince.com;
- the Registrar to the Issue at www.skylinert.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinert.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: <https://www.skylinert.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: www.skylinert.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinert.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase -I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id atipo@skylinert.com.



SUNREST LIFESCIENCE LIMITED
CIN: L74999GJ2017PLC099606

Registered Office: D-608, West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India ; Tel. No.: +91 99250 58245/43;
Email: info@sunrestlifesceince.com Website: www.sunrestlifesceince.com
Contact Person: Nabil Ansari, Company Secretary & Compliance Officer



SKYLINE FINANCIAL SERVICES PRIVATE LIMITED
D-153/A, First Floor, Okhla Industrial Area, Phase -I, New Delhi – 110020
Tel: +91-11-4045 0193-97 Email: ipo@skylinert.com Website: www.skylinert.com
Investors Grievance E-mail: grievances@skylinert.com Contact Person: Mr. Anuj Rana
SEBI Registration Number: INR00003241

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

For, Sunrest Lifescience Limited
Sd/-
Nikhilkumar Y Thakkar
Managing Director
Din: 07662800

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEIL at www.nseindia.com and, Company at www.sunrestlifesceince.com, website of the Registrar to the Issue at www.skylinert.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

TAI INDUSTRIES LIMITED CIN: L01222WB1983PLC059695					
Registered Office : Arihant Building, 3rd Floor, 53A, Mirza Ghalib Street, Kolkata - 700 016					
Phone No. : (033) 4041 6666					
E-mail : info@taiind.com Website : www.taiind.com					
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026					
(₹ in Lakhs)					
Sl. No.	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
1	Total Income from Operations	3,578.59	6,164.57	2,549.04	15,966.57
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(43.21)	4.70	1.08	25.89
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.70	1.08	25.89
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.29	0.10	9.55
5	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(41.68)	(53.31)	27.75	(43.10)
6	Paid up Equity Share Capital (₹ 10/- each)	600.00	600.00	600.00	600.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2,360.51
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) - 1. Basic (₹) 2. Diluted (₹)	(0.72) (0.72)	0.07 0.07	0.00 0.00	0.16 0.16
Note : a) The above is an extract of the detailed format of Quarterly/ Year ended Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the website of the Stock Exchange at www.bseindia.com and also on the website of the Company, at www.taiind.com					
For Tai Industries Limited Rohan Ghosh (Managing Director) (DIN - 00032965)					
Place : Kolkata Date : 12th August, 2026					



Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpet, Solapur 413 213, India.

Corporate Office: Technopolis Knowledge Park, A Wing, Office no. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093

Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963

Website: www.alivus.com Email: complianceofficer@alivus.com

NOTICE

NOTICE is hereby given that the 15th Annual General Meeting (AGM) of the Members of the Company will be held on **Tuesday, September 8, 2026 at 3.00 p.m. (IST)** through two-way Video Conferencing (VC)/Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (together referred to as "Circulars").

The Notice setting out the Ordinary and Special business(es) to be transacted during the AGM and the Integrated Annual Report 2025-26 (Annual Report) has been sent by email to the members whose email IDs are registered with the Depository Participant (DP) or the Company. The email dispatch has been completed on August 11, 2026. Further the Company is sending a letter providing the web-link where complete details of the Annual Report is available, to those members who have not registered their email IDs.

The Notice of the AGM and the Annual Report are available on the website of the Company, i.e., www.alivus.com and on the websites of the stock exchanges, i.e., www.bseindia.com and www.nseindia.com. The Notice of the AGM is also available on the website of NSDL i.e. www.evoting.nsdl.com. The Annual Report can also be accessed by scanning the QR code.

In terms of the provisions of Section 108 and other applicable provisions, if any, of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended, and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is pleased to provide to its members the facility to exercise their right to vote on the resolutions proposed to be passed during the AGM by electronic means. The Company



This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCIENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifescience.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifescience.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS "ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

* Assuming full subscription and receipt of all Call Monies with respect to Rights Equity Shares.

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED

ISSUE OPENS ON
TUESDAY AUGUST 18, 2026

LAST DATE FOR ON MARKET RENUNCIATION*
FRIDAY AUGUST 28, 2026

ISSUE CLOSES ON#
WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*

Simple, Safe, Smart way of making an application - Make use of it
*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INE0PLZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCIENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares entitled to;
- Number of Rights Equity Shares applied for within the Rights Entitlements;
- Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Rights Equity Shares applied for;
- Total amount paid at the rate of Rs.35/- per Rights Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:

"I/We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/We understand the Rights Equity Shares referred to in this application are being offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/We understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/We confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/We satisfy, and each account for which I/We are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/We hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.

I/We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinert.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlement in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER INTO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only in Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (6) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e. Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEIL (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEIL") should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by NSEIL, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" on page 94 of the Letter of Offer.

Banker To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e. Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifescience.com;
- the Registrar to the Issue at www.skylinert.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinert.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: <https://www.skylinert.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: www.skylinert.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinert.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id atipo@skylinert.com.

COMPANY DETAILS	
SUNREST LIFESCIENCE LIMITED CIN: L74999GJ2017PLC099606 Registered Office: D-608, West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India ; Tel. No.: +91 99250 58245/43; Email: info@sunrestlifescience.com Website: www.sunrestlifescience.com Contact Person: Nabil Ansari, Company Secretary & Compliance Officer	

REGISTRAR TO THE ISSUE	
SKYLINE FINANCIAL SERVICES PRIVATE LIMITED D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020 Tel: +91-11-4045 0193-97 Email: ipo@skylinert.com Website: www.skylinert.com Investors Grievance E-mail: grievances@skylinert.com Contact Person: Mr. Anuj Rana SEBI Registration Number: INR00003241	

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

For, Sunrest Lifescience Limited
Sd/-
Nikhilkumar Y Thakkar
Managing Director
Din: 07662800

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEIL at www.nseindia.com and, Company at www.sunrestlifescience.com, website of the Registrar to the Issue at www.skylinert.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

TAI INDUSTRIES LIMITED					
CIN: L01222WB1983PLC059695					
Registered Office : Arihant Building, 3rd Floor, 53A, Mirza Ghalib Street, Kolkata - 700 016					
Phone No. : (033) 4041 6666					
E-mail : info@taiind.com Website : www.taiind.com					
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026					
₹ (in Lakhs)					
Sl. No.	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
1	Total Income from Operations	3,578.59	6,164.57	2,549.04	15,966.57
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(43.21)	4.70	1.08	25.89
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.70	1.08	25.89
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.29	0.10	9.55
5	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(41.68)	(53.31)	27.75	(43.10)
6	Paid up Equity Share Capital (₹ 10/- each)	600.00	600.00	600.00	600.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2,360.51
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) -				
1. Basic (₹)		(0.72)	0.07	0.00	0.16
2. Diluted (₹)		(0.72)	0.07	0.00	0.16

Note : a) The above is an extract of the detailed format of Quarterly/ Year ended Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the website of the Stock Exchange at www.bseindia.com and also on the website of the Company, at www.taiind.com.

For Tai Industries Limited

Rohan Ghosh

(Managing Director)

(DIN - 00032965)

Place : Kolkata
Date : 12th August, 2026



Alivus Life Sciences Limited

(formerly Glenmark Life Sciences Limited)

This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifestyle.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifestyle.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS "ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

* Assuming full subscription and receipt of all Call Monies with respect to Rights Equity Shares.

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCENCE LIMITED

ISSUE OPENS ON	LAST DATE FOR ON MARKET RENUNCIATION*	ISSUE CLOSING ON#
TUESDAY AUGUST 18, 2026	FRIDAY AUGUST 28, 2026	WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*

*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INE0PLZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescence Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares entitled to;
- Number of Rights Equity Shares applied for within the Rights Entitlements;
- Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Rights Equity Shares applied for;
- Total amount paid at the rate of Rs.35/- per Rights Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:

"I/We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/We understand the Rights Equity Shares referred to in this application are being offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/We understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/We confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/We satisfy, and each account for which I/We are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/We hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.

I/We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinert.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date.

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlements in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER INTO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only in Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescence Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (6) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e., Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEIL (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEIL") should not in any way, be deemed or construed that the Letter of Offer has been cleared or approved by NSEIL, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" on page 94 of the Letter of Offer.

Banker To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e., Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifestyle.com;
- the Registrar to the Issue at www.skylinert.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinert.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: <https://www.skylinert.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: www.skylinert.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinert.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id atipo@skylinert.com.

COMPANY DETAILS
SUNREST LIFESCENCE LIMITED CIN: L74999GJ2017PLC099606 Registered Office: D-608, West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India ; Tel. No.: +91 99250 58245/43; Email: info@sunrestlifestyle.com Website: www.sunrestlifestyle.com Contact Person: Nabil Ansari, Company Secretary & Compliance Officer

REGISTRAR TO THE ISSUE
SKYLINE FINANCIAL SERVICES PRIVATE LIMITED D-153/A, First Floor, Okhla Industrial Area, Phase - I, New Delhi – 110020 Tel: +91-11-4045 0193-97 Email: ipo@skylinert.com Website: www.skylinert.com Investors Grievance E-mail: grievances@skylinert.com Contact Person: Mr. Anuj Rana SEBI Registration Number: INR00003241

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

For, Sunrest Lifescence Limited
Sd/-
Nikhilkumar Y Thakkar
Managing Director
Din: 07662800

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEIL at www.nseindia.com and, Company at www.sunrestlifestyle.com, website of the Registrar to the Issue at www.skylinert.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

TAI INDUSTRIES LIMITED					
CIN: L01222WB1983PLC059695					
Registered Office : Arihant Building, 3rd Floor, 53A, Mirza Ghalib Street, Kolkata - 700 016					
Phone No. : (033) 4041 6666					
E-mail : info@taiind.com Website : www.taiind.com					
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026					
₹ (in Lakhs)					
Sl. No.	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
1	Total Income from Operations	3,578.59	6,164.57	2,549.04	15,966.57
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(43.21)	4.70	1.08	25.89
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.70	1.08	25.89
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(43.21)	4.29	0.10	9.55
5	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(41.68)	(53.31)	27.75	(43.10)
6	Paid up Equity Share Capital (₹ 10/- each)	600.00	600.00	600.00	600.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2,360.51
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) -				
	1. Basic (₹)	(0.72)	0.07	0.00	0.16
	2. Diluted (₹)	(0.72)	0.07	0.00	0.16

Note : a) The above is an extract of the detailed format of Quarterly/ Year ended Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the website of the Stock Exchange at www.bseindia.com and also on the website of the Company, at www.taiind.com.

For Tai Industries Limited
 Rohan Ghosh
 (Managing Director)
 (DIN - 00032965)

Place : Kolkata
 Date : 12th August, 2026

ALIVUS
 LIFESCIENCES
 Live every day

Alivus Life Sciences Limited
 (formerly Glenmark Life Sciences Limited)

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpet, Solapur 413 213, India.

Corporate Office: Technopolis Knowledge Park, A Wing, Office no. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093

Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963

Website: www.alivus.com; Email: complianceofficer@alivus.com

NOTICE

NOTICE is hereby given that the 15th Annual General Meeting (AGM) of the Members of the Company will be held on **Tuesday, September 8, 2026 at 3.00 p.m. (IST)** through two-way Video Conferencing (VC)/Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (together referred to as "Circulars").

The Notice setting out the Ordinary and Special business(es) to be transacted during the AGM and the Integrated Annual Report 2025-26 (Annual Report) has been sent by email to the members whose email IDs are registered with the Depository Participant (DP) or the Company. The email dispatch has been completed on August 11, 2026. Further the Company is sending a letter providing the web-link where complete details of the Annual Report is available, to those members who have not registered their email IDs.

The Notice of the AGM and the Annual Report are available on the website of the Company, i.e., www.alivus.com and on the websites of the stock exchanges, i.e., www.bseindia.com and www.nseindia.com. The Notice of the AGM is also available on the website of NSDL i.e. www.evoting.nsdl.com. The Annual Report can also be accessed by scanning the QR code.



This is only an advertisement for information purposes and for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document.

SUNREST LIFESCIENCE LIMITED

Corporate Identification Number: L74999GJ2017PLC099606

Registered Office: D-608 West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051

Website: www.sunrestlifescience.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifescience.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHULAL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10thAUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED 'TERMS OF THE ISSUE' BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

* Assuming full subscription and receipt of all Call Monies with respect to Rights Equity Shares.

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCIENCE LIMITED

ISSUE OPENS ON

TUESDAY AUGUST 18, 2026

LAST DATE FOR ON MARKET RENUNCIATION*

FRIDAY AUGUST 28, 2026

ISSUE CLOSES ON#

WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

**Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.*

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.



Simple, Safe, Smart way of making an application - Make use of it

*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INE0PLZ20020** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") ("Demat Escrow Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.

Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBAAccounts.

Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?do=RecognisedFpi=yes&intmid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DIL/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.

Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 78 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.

An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being SUNREST LIFESCIENCE LIMITED
- Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
- Registered Folio Number/DP and Client ID No
- Number of Equity Shares held as on Record Date;
- Allotment option - only dematerialised form;
- Number of Rights Equity Shares entitled to;
- Number of Rights Equity Shares applied for within the Rights Entitlements;
- Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Rights Equity Shares applied for;
- Total amount paid at the rate of Rs. 35/- per Rights Equity Share;
- Details of the ASBAAccount such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
- All such Eligible Equity Shareholders, shall be deemed to have accepted the following:

"I/ We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. I/ we understand the Rights Equity Shares referred to in this application are being offered and sold in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/ we understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/ we confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/ We satisfy, and each account for which I/ we are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/ we hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.

I/ We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinerta.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBAAccounts on or before the Issue Closing Date

Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.

Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlement in respect of any such Application Form.

THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER INTO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.

Rights Entitlements may not be transferred or sold to any person in the United States.

Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Allotment Only In Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (6) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details) records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e. Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAT ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.

DISCLAIMER CLAUSE OF NSEIL (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEIL") should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by NSEIL, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" on page 94 of the Letter of Offer.

Banker To The Issue And Refund Bank: Axis Bank Limited

Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.

Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispached only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. In accordance with the above, the dispatch of the Letter of Offer, the Rights Entitlement Letter along with the Application Form has been completed on August 12, 2026 by Registrar to the Issue, i.e. Skyline Financial Services Private Limited and the Company, to all the Eligible Equity Shareholders of the Company, whose names appeared in the Register of Members/Beneficial Owners of the Company as on the Record date, i.e., Monday, August 10, 2026.

Investors can access the Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the websites of

- our Company at www.sunrestlifescience.com;
- the Registrar to the Issue at www.skylinerta.com; and
- the Stock Exchanges at www.nseindia.com.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., https://www.skylinerta.com/display_entitlement.php) by entering their DP ID and Client ID and PAN.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors:
<https://www.skylinerta.com/frequently-asked-questions.php>
- Update of e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: www.skylinerta.com
- Update of Indian address can be sent to Registrar at email id ipo@skylinerta.com or by way of Registered post/Courier at Skyline Financial Services Private Limited D-153/A, First Floor, Okhla Industrial Area, Phase – I, New Delhi – 110020
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders at email id atipo@skylinerta.com.



SUNREST LIFESCIENCE LIMITED

CIN: L74999GJ2017PLC099606

Registered Office: D-608, West Gate, Nr. Brooklin Tower, YMCA Club, Nr. S G Highway, Makarba, Jivraj Park, Ahmedabad - 380051, Gujarat, India ; Tel. No.: +91 99250 58245/43;

Email: info@sunrestlifescience.com Website: www.sunrestlifescience.com

Contact Person: Nabil Ansari, Company Secretary & Compliance Officer



REGISTRAR TO THE ISSUE

SKYLINE FINANCIAL SERVICES PRIVATE LIMITED

D-153/A, First Floor, Okhla Industrial Area, Phase – I, New Delhi – 110020

Tel: +91-11-4045 0193-97 Email: ipo@skylinerta.com Website: www.skylinerta.com

Investors Grievance E-mail: grievances@skylinerta.com Contact Person: Mr. Anuj Rana

SEBI Registration Number: INR000003241

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post- Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, see "Terms of the Issue" beginning on page 96 of the Letter of Offer.

For, Sunrest Lifescience Limited
Sd/-
Nikhilkumar Y Thakkar
Managing Director
Din: 07662800

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEIL at www.nseindia.com and, Company at www.sunrestlifescience.com, website of the Registrar to the Issue at www.skylinerta.com. Potential investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

अभिषेक बनर्जी के निजी सहायक की याचिका पर तत्काल सुनवाई से इनकार

कोलकाता, 12 अगस्त (भाषा) ।

कलकत्ता हाई कोर्ट ने तृणमूल नेता एवं सांसद अभिषेक बनर्जी के निजी सहायक सुमित राय की उस याचिका पर तत्काल सुनवाई करने से बुधवार को इनकार कर दिया, जिसमें राय ने अपने खिलाफ दर्ज कुछ मामलों में पुलिस की दंडात्मक कार्रवाई से अंतरिम सुरक्षा का अनुरोध किया है।

सुप्रीम कोर्ट और हाई कोर्ट ने इससे पहले राय को क्रमशः जमीन हड़पने और नौकरियों के बदले नकदी घोटाले से जुड़े मामलों में राहत दी थी। न्यायमूर्ति सौगत भट्टाचार्य ने याचिका को तत्काल सुनवाई के लिए सूचीबद्ध करने से इनकार करते हुए कहा कि अदालत के समक्ष इसी तरह कई काई याचिकाएं लंबित हैं और राय की याचिका को सूची में ऊपर लाना संभव नहीं है। उन्होंने कहा कि याचिका के क्रम के अनुसार ही उस पर सुनवाई की जाएगी। राय

के वकील ने कहा कि इन मामलों में पुलिस की दंडात्मक कार्रवाई से अंतरिम सुरक्षा के लिए याचिका पर तत्काल सुनवाई का अनुरोध किया था। सुप्रीम कोर्ट ने बंगाल के शालबोनी में जमीन हड़पने के मामले में राय की गिरफ्तारी पर छिछले सप्ताह रोक लगा दी थी और उन्हें जारी जांच में पूरा सहयोग करने का निर्देश दिया था। राय को हाई कोर्ट ने नौकरियों के बदले कथित नकदी घोटाले से जुड़े एक अन्य मामले में भी अग्रिम जमानत दी थी।

बंगाल में जल्द होगी सरकारी पदों पर भर्ती प्रक्रिया शुरू

कोलकाता, 12 अगस्त (जनसत्ता) ।

राज्य सरकार की ओर से रिक्त पड़े पदों पर जल्द ही भर्ती प्रक्रिया शुरू की जाएगी। इसके तहत पश्चिम बंगाल लोक सेवा आयोग, बंगाल पुलिस भर्ती बोर्ड, स्कूल शिक्षा आयोग और वेस्ट बंगाल कर्मचारी चयन आयोग का कहना है कि अगले कुछ महीनों के भीतर ही पश्चिम बंगाल में खाली एक लाख से अधिक पदों पर नियुक्ति प्रक्रिया संपन्न कर दी जाएगी।

बीते दिनों मुख्यमंत्री शुभेंद्रु अधिकारी ने स्वस्थानित संस्थाओं

के अधिकारियों के साथ एक बैठक में लंबे समय से खाली पदों पर नियुक्ति और परीक्षा परिणाम घोषित किए जाने को लेकर ख़ासा जोर दिया था।

इस बीच, पीएससी की ओर से बताया गया है कि 54 विभागों में 2 हजार 490 ग्रुप ए पदों पर भर्ती की प्रक्रिया चल रही है। इसके साथ ही ग्रुप बी के 2 हजार 848 और ग्रुप सी के 12 हजार 376 पदों पर नियुक्ति की प्रक्रिया भी चल रही है। इसके लिए 12 लाख 65 हजार लोगों ने परीक्षा दी थी, परीक्षा परिणाम घोषित किया जाना बाकी है।

लोक्सभा अध्यक्ष बिरला से मिले अभिषेक बागी सांसदों को लेकर जल्द निर्णय लेने का आग्रह किया

नई दिल्ली, 12 अगस्त (भाषा) ।

तृणमूल कांग्रेस के नेता अभिषेक बनर्जी ने बुधवार को कहा कि उन्होंने लोकसभा अध्यक्ष ओम बिरला से मुलाकात कर आग्रह किया है कि वह पार्टी के 20 बागी सांसदों को अयोग्य करार देने की मांग संबंधी लंबित याचिकाओं पर जल्द फैसला करें।

बनर्जी ने यह भी कहा कि यदि लोकसभा अध्यक्ष ने कानून और न्यायिक निर्देशों के तहत निर्धारित अधि में इन याचिकाओं पर फैसला नहीं करते हैं तो मैं सुप्रीम कोर्ट का रुख करने और उसके हस्तक्षेप का अनुरोध करने के लिए मजबूर हो जाऊंगा। बनर्जी ने कहा कि उन्होंने और तृणमूल के अन्य सांसदों ने बार-बार बिरला के समक्ष यह मामला उठाया है। उन्होंने कहा कि मानसून सत्र शुरू होने के बाद 23 या 24 जुलाई को मैंने अध्यक्ष के समक्ष इस मुद्दे को उठाया था।

बंगाल एसटीएफ की कार्रवाई संदिग्ध पाकिस्तानी नागरिक सहित दो लोग गिरफ्तार

कोलकाता, 12 अगस्त (भाषा) ।

पश्चिम बंगाल पुलिस के विशेष कार्य बल (एसटीएफ) ने बुधवार को भारत-बांग्लादेश सीमा के पास से दो लोगों को गिरफ्तार किया है, जिनमें से एक के पाकिस्तानी नागरिक होने का संदेह है। अधिकारियों के अनुसार, पाकिस्तान के फैसलाबाद निवासी राणा रऊफ उर्फ वहाब आलम को उत्तर 24 परगना जिले के बन्गांव से गिरफ्तार किया गया। गोपनीय सूचना के आधार पर एसटीएफ की टीम ने बन्गांव इलाके में तलाश अभियान चलाया और रऊफ को गिरफ्तार कर लिया। जांचकर्ताओं के अनुसार, रऊफ के पाकिस्तानी खुफिया एजेंसी आइएसआइ से संबंध हो सकते हैं। वे भारत में रऊफ की गतिविधियों, संपर्कों और आवाजाही की जांच कर रहे हैं। अधिकारियों ने बताया कि मंगलवार देर रात टोपसिया से एक अन्य व्यक्ति को गिरफ्तार किया गया था, जिसका कथित तौर पर रऊफ के साथ संबंध है। उसकी पहचान

उजागर नहीं की गई है। अधिकारियों के मुताबिक, उसने रऊफ की कई तरह से मदद की थी। जांचकर्ताओं के अनुसार, रऊफ 2012 में नेपाल के रास्ते अवैध रूप से भारत में दाखिल हुआ था। एक अधिकारी ने बताया कि भारत में प्रवेश करने और बाद में पश्चिम बंगाल में बसने से पहले वह कुछ समय तक नेपाल में रहा था। अधिकारियों के अनुसार, रऊफ देश में विभिन्न टेनों और सशस्त्र बलों की गतिविधियों पर नजर रख रहा था। एसटीएफ के एक अधिकारी ने कहा कि हम यह पता लगाने की भी कोशिश कर रहे हैं कि वह किस तरह की जानकारी जुटा रहा था और क्या वह जानकारी देश के बाहर किसी को भेजी जा रही थी। उन्होंने कहा कि टोपसिया से गिरफ्तार व्यक्ति से पूछताछ की जा रही है ताकि रऊफ के साथ उसके संबंधों की गहराई का पता लगाने के साथ ही इस मामले में किसी अन्य व्यक्ति की संलिप्तता का भी पता लगाया जा सके।

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated August 07, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., NSEIL at www.nseindia.com and, Company at www.sunrealtiescience.com, website of the Registrar to the Issue at www.skylintera.com. Potential investors should note that investment in equity shares involves a high degree of risk and is requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 24 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

SYMBIOX INVESTMENT & TRADING CO. LTD				
CIN No: L65993WB1979PLC032012				
221, RABINDRA SARANI, 3RD FLOOR, ROOM NO-1, KOLKATA -700007				
Email ID. symvioxinvestment100@gmail.com; www. symbioxinvestment.com;				
UNAUDITED FINANCIAL RESULT FOR QUARTER				
ENDED ON 30TH JUNE, 2026				
Rs. (Lacs except EPS)				
PARTICULARS	Quarter ending 30/06/2026	Quarter ending 31/03/2026	Quarter ending 30/06/2025	Year ending 31/03/2026
	Unaudited	Audited	Unaudited	Audited
Total income from operations(net)	10.45	1.65	9.04	20.58
Net Profit/ (Loss) from Ordinary				
Activities after tax	7.73	1.22	6.69	15.23
Net Profit/ (Loss) for the period after tax (after Extraordinary items)	7.73	1.22	6.69	15.23
Equity Share Capital	312,873,300	312,873,300	312,873,300	312,873,300
Reserves (excluding Revaluation				
Reserve as shown in the balance sheet of previous year)	-	-	-	58.90
Earning Per Share (of Rs. 10/-each)				
Basic	0.025	0.004	0.021	0.049
Diluted	0.025	0.004	0.021	0.049
Note:				
The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI(Listing Obligations and Other Disclosure Requirements) Regulations, 2015				
For Symbiox Investment & Trading Company Limited				
Sd/-				
Samit Ray				
Managing Director				
DIN NO. 08406285				
				
Place: Kolkata				
Date: 12.08.2026				



સિક્કો ઇન્ડસ્ટ્રીઝ લિમિટેડ
સીન: એલ૩૫૧૦૫૭જે૨૦૦૧ીએલ૩ી૦૩૭૩૨૯
રજિસ્ટર્ડ ઓફિસ: ૫૦૮, ઈસ્ટોન એવિન્યુ, જુન મંદિર નજીક, મહાલાક્ષ્મી પીક અપ સ્ટેન્ડ નજીક, વજુપુર, અમદાવાદ - ૩૮૦૦૫૧; ટેલિફોન: ૯૮૧ ૭૯-૬૬૧૬૮૮૫૦/૬૬૧૬૮૮૫૧
વેબસાઇટ: www.sikkoindia.com, ઈમેલ: compliance@sikkoindia.com

૩મી જૂન, ૨૦૨૬ ના રોજ પૂરા થયેલા ત્રિમાસિક ગાળા ના એકીકૃત નાણાકીય પરિણામ નો અર્ક
(ઈ.પી.એસ. કિલોચ રૂપ લાખમાં)

વિગતો	ત્રિમાસિક ગાળા ૦૧/૦૬/૨૦૨૬	ત્રિમાસિક ગાળા ૦૪/૦૬/૨૦૨૫	નાણાકીય વર્ષ ૩૧/૦૩/૨૦૨૬
	ક્રયા	ક્રયા	પાકા
ક્રમગીતીમાંની કુલ આવક	૧,૭૭૮.૦૪	૧,૮૧૪.૬૫	૬,૬૪૧.૩૬
સમયગાળા માટે ચોખ્ખો નફો / (નુકસાન) (કર, અપવાદરૂપ અને / અથવા અસાધારણ વસ્તુઓ પછી)	૪૧૭.૫૧	૩૦૧.૮૦	૬૨૮.૫૬
સમયગાળા માટે કર પહેલાના ચોખ્ખો નફો / (નુકસાન) (અપવાદરૂપ અને / અથવા અસાધારણ વસ્તુઓ પછી)	૪૧૭.૫૧	૩૦૧.૮૦	૬૨૮.૫૬
સમયગાળા માટે કર પછીના ચોખ્ખો નફો / (નુકસાન) (અપવાદરૂપ અને / અથવા અસાધારણ વસ્તુઓ પછી)	૩૧૨.૫૫	૨૧૭.૮૧	૫૧૦.૪૬
સમયગાળા માટે કુલ વ્યાક આવક (સમયગાળા માટે નફો / (નુકસાન) અને કરની બાદ અન્ય આવક (કર પછી) સમાવેશ થાય છે)	૩૧૨.૫૫	૨૧૭.૮૧	૫૧૦.૪૬
ફિન્ટી શેર મૂલ્ય	૪,૩૬૮.૦૦	૨,૧૮૪.૦૦	૪,૩૬૮.૦૦
અનામત (વગલો વર્ધના પાછી કરેલી બેલેન્સ શીટ મુજબ મુલ્યાંકન અનામતને બાદ કર્યા પછી)	-	-	૪,૨૬૦.૩૮
શેર ઇલેક્ટ્રોનિક વ્યાજ અને બંધ ક્રમગીતી માટે -			
બેંકો: (સામાન્ય ત્રિમાસિક ગાળા માટે ચાર્જીકરણ કર્યા વગર)	૦.૦૭	૦.૦૫	૦.૧૨
કલ્પરૂપ: (સામાન્ય ત્રિમાસિક ગાળા માટે ચાર્જીકરણ કર્યા વગર)	૦.૦૭	૦.૦૫	૦.૧૨
નોંધ: ૧. ઉપરોક્ત નાણાકીય એ સેબી સુચિઓ નિયમનોના નિયમન ૩૩ હેઠળ નેશનલ સ્ટોક એક્સચેન્જ ઓફ ઈન્ડિયા લિમિટેડ સાથે ફાઇલ કરેલા ત્રિમાસિક ગાળા ના નાણાકીય પરિણામોના વિગતવાર બંધારણનો એક અર્ક છે. આના ત્રિમાસિક નાણાકીય પરિણામો સ્ટોક એક્સચેન્જની વેબસાઇટ www.nseindia.com પર તેમજ કંપનીની વેબસાઇટ www.sikkoindia.in પર ઉપલબ્ધ છે અને નીચે આપેલા QR કોડને સ્કેન કરીને તે એક્સેસ કરી શકાય છે.			



૨. એકલ ક્રયા નાણાકીય પરિણામોની વધારાની માહિતી નીચે મુજબ છે:

વિગતો	ત્રિમાસિક ગાળા ૦૧/૦૬/૨૦૨૬	ત્રિમાસિક ગાળા ૦૪/૦૬/૨૦૨૫	નાણાકીય વર્ષ ૩૧/૦૩/૨૦૨૬
	ક્રયા	ક્રયા	પાકા
ક્રમગીતીમાંની કુલ આવક	૧૭૭૮.૦૩	૧૮૧૪.૬૫	૬૬૪૧.૩૪
સમયગાળા માટે કર પહેલાના ચોખ્ખો નફો / (નુકસાન) (અપવાદરૂપ અને / અથવા અસાધારણ વસ્તુઓ પછી)	૪૧૭.૬૮	૩૦૧.૮૦	૬૨૮.૬૭
સમયગાળા માટે કર પછીના ચોખ્ખો નફો / (નુકસાન) (અપવાદરૂપ અને / અથવા અસાધારણ વસ્તુઓ પછી)	૩૧૨.૭૨	૨૧૭.૮૧	૫૧૦.૫૮

સિક્કો ઇન્ડસ્ટ્રીઝ લિમિટેડ વતી
Sd/-
જયદીભાઈ મોહનભાઈ કુમારી
મેનેજિંગ ડિરેક્ટર
ડીન: ૦૦૫૯૭૮૦૭

સ્થાન: અમદાવાદ
તારીખ: ૧૨/૦૮/૨૦૨૬

CIN: - L74999GJ2017PLC099606
Corporate Office: 6th Floor 608, West gate D-Block, S G Highway, Makarba, Ahmedabad – 380051
Mo.: 9925058245/43 **Web:** - www.sunrestlifestyle.com
Email id:- info@sunrestlifestyle.com



NOTICE OF NINTH ANNUAL GENERAL MEETING OF THE COMPANY TO BE HELD THROUGH VIDEO CONFERENCING (VC) OF OTHER AUDIO-VISUAL MEANS
1. Notice is hereby given that the **09th Annual General Meeting ("AGM")** of the Company will be convened through Video Conferencing/Other Audio Video Means on **Monday, 07th September, 2026 at 12:30 P.M.** IST in compliance with the applicable provisions of the Companies Act, 2013 and rules framed there under and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with General Circular No. 09/2024 dated September 19, 2024 read with the circulars issued earlier in this regard (Collectively referred to as "MCA Circulars" and Securities and Exchange Board of India ("SEBI") Circular Nos. SEBI/HO/CFD/CFD-POD-2/P/CIR/2024/133 dated October 3, 2024 read with the circulars issued earlier in this regard (Collectively referred to as "SEBI Circulars") respectively.
2. The notice of the AGM and the Annual Report for the financial year 2025 - 26 are being sent only through electronic mode to all the shareholders whose e-mail addresses are registered with the Company/Registrar and Transfer Agent ("RTA"/Depository Participant(s)).
3. A letter containing the weblink of the Annual Report for the financial year 2025 - 26 is being sent at the registered address of the shareholders whose e-mail addresses are not registered with the Company/RTA/Depository Participant(s)).
4. Shareholders holding shares in demat mode whose e-mail addresses are not registered may get their e-mail address registered with their respective Depository Participant(s), and Shareholders holdings shares in physical mode are requested to update their E-mail addresses with Company's RTA i.e. **Skyline Financial Services Pvt Ltd**, through <https://www.skylinertat.com> or by writing to info@skylinertat.com
5. Pursuant to above circulars, the requirement of sending physical copies of the Annual Report has been dispensed with, Physical copies of the Annual Report 2025 - 26 will be sent only to those shareholders who specifically request for the same, however, we urge shareholders to support our commitment to environmental protection by choosing to receive Company's communications through E-mail.
6. The Notice of the AGM and the Annual Report will also be made available on the websites of the Company (<https://sunrestlifestyle.com>), concerned Stock Exchanges, i.e NSE Limited (www.nseindia.com) and RTA (www.skylinertat.com)
7. The Company will be providing facility of remote e-voting to the shareholders through e voting agency namely **"National Securities Depository Limited (NSDL)**. Shareholders unable to vote through remote e-voting will be able to do e-voting at the AGM by using their Remote e-voting credentials at <https://eservices.nsdl.com/SecureWeb/e-voting/e-votinglogin.jsp>. The detailed procedure for remote e-voting/e-voting during the AGM will be provided in the Notice of the AGM.
8. The remote e-voting period begins on **Friday, 04th September, 2026 at 9:00 A.M.** and ends on **Sunday, 06th September, 2026 at 5:00 P.M. (IST)**. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. **Friday, 29th August, 2026**, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being **Friday, 29th August, 2026**.
9. The Board of Directors of the Company has appointed **CS JINANG DINESHKUMAR SHAH** Proprietor of **M/S Jinang Shah & Associates**, Practicing Company Secretary as the Scrutinizer for conducting voting process in fair and transparent manner.
10. The Detailed instruction for AGM through VC/OAVM and casting the vote through remote E-voting at the AGM is provided at the notice of AGM. Members are requested to carefully go through the same. Members who need assistance before or during the AGM regarding e-voting facility and/or VC/OAVM facility, can send a request at evoting@nsdl.com or call at 022-4886 7000
11. Person entitled to attend and vote at the meeting, may vote in person or by proxy/through authorize representative, provided that all proxies in the prescribed form/authorization duly signed by the person entitled to attend and vote at the meeting are deposited at the registered office of the company not later than 48 hours before the meeting.

For and on Behalf of the Board of Directors of
SUNREST LIFESCENCE LIMITED
Sd/-
NIKIL KUMAR YASHVNTAL THAKKAR
Managing Director (DIN: 07962800)

Date: 13.08.2026
Place: Ahmedabad



SUNREST LIFESCENCE LIMITED
Corporate Identification Number: L74999GJ2017PLC099606
Registered Office: D-608 West Gate, Nr. Brooklin Tower, YMCA Club, Nr. SG Highway, Makarba, Jivraj Park, Ahmedabad, Gujarat, India-380051
Website: www.sunrestlifestyle.com; Tel No: +91 99250 58245/43; Email Id: info@sunrestlifestyle.com; Contact person: Nabil Ansari- Company Secretary and Compliance Officer

PROMOTER OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHUL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR
FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCENCE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY

ISSUE OF UP TO 4291200 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF 35 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 25 PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO RS. 1501.92 LAKHS ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 RIGHTS EQUITY SHARE FOR EVERY 01 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON MONDAY 10th AUGUST, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 96 OF THIS LETTER OF OFFER.

*Assuming full subscription and receipt of all Calls Monies with respect to Rights Equity Shares.

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF SUNREST LIFESCENCE LIMITED

ISSUE OPENS ON
TUESDAY AUGUST 18, 2026

LAST DATE FOR ON MARKET RENUNCIATION*
FRIDAY AUGUST 28, 2026

ISSUE CLOSING ON#
WEDNESDAY SEPTEMBER 02, 2026

Pursuant to the Streamlining of Rights Issue Circular, SEBI has introduced the concept of credit of Rights Entitlements into the demat accounts of the Eligible Equity Shareholders, which can be renounced by them by way of On Market Renunciation or Off Market renunciation.

**Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.*

The credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made only in dematerialized form. For details, please see "Terms of the Issue" on page 98 of the Letter of Offer

Our Board will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*
*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below

PROCEDURE FOR APPLICATION IN THIS ISSUE
In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars, all Investors desiring to make an application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their application through ASBA. For details see, "Making an Application through the ASBA process" on page 100 of the Letter of Offer.
CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS
Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Master Circular and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders will be credited in their respective demat accounts and shall be admitted for trading on the Stock Exchanges under the **ISIN: INE0PLZ2002** subject to requisite approvals. For details of credit of the Rights Entitlements see "Terms of the Issue - Credit of Rights Entitlements in Demat Accounts of Eligible Equity Shareholders" on page 111 of the Letter of Offer.
In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, in the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.
Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.
PLEASE NOTE THAT CREDIT OF RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE INVESTORS TO THE RIGHTS EQUITY SHARES AND INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED "TERMS OF THE ISSUE- PROCEDURE FOR APPLICATION" ON PAGE 99 OF THE LETTER OF OFFER.
Procedure For Application Through the ASBA Process: Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.
Investors should ensure that they have correctly submitted the Application Form, or have otherwise provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.
For the list of banks which have been notified by SEBI to act as SCSBs for ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?do=recognition&Pj=ys&intMid=35>. For details on Designated Branches of SCSBs collecting the Application Form, please refer the above-mentioned link. Please note that subject to SCSBs complying with the requirements of SEBI Circular No. CIR/CFD/DLI/13/2012 dated September 25, 2012 within the periods stipulated therein, ASBA applications may be submitted at the Designated Branches of the SCSBs, in case of Applications made through ASBA facility.
PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, SEE "ALLOTMENT ADVICE OR REFUND/UNBLOCKING OF ASBA ACCOUNT" ON PAGE 119 OF THE LETTER OF OFFER.
Applications on Plain Paper under ASBA process: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to the Issue on plain paper in case of non-receipt of Application Form as detailed above and only such plain paper applications which provide all the details required in terms of Regulation 76 of SEBI ICDR Regulations shall be accepted by SCSBs. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to the Issue on plain paper with the same details as per the Application Form that is available on the website of the Registrar, or the Stock Exchanges.
An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.
Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently. The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:
1. Name of our Company, being SUNREST LIFESCENCE LIMITED
2. Name and address of the Eligible Equity Shareholder including joint (in the same order and as per specimen recorded with our Company or the Depository);
3. Registered Folio Number/DP and Client ID No
4. Number of Equity Shares held as on Record Date;
5. Allotment option- only dematerialised form;
6. Number of Rights Equity Shares entitled to;
7. Number of Rights Equity Shares applied for within the Rights Entitlements;
8. Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
9. Total number of Rights Equity Shares applied for;
10. Total amount paid at the rate of Rs. 35/- per Rights Equity Share;
11. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
12. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/ FCNRI NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
13. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to the Issue;
14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
16. All such Eligible Equity Shareholders, shall be deemed to have accepted the following:
"I/ We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the (U.S. Securities Act). I/ we understand the Rights Equity Shares referred to in this application have been offered and sold in offshore transactions in compliance with Regulation S under the U.S. Securities Act ("Regulation S") to Eligible Equity Shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions. I/ we understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements in the United States. I/ we confirm that I am/ we are (a) not in the United States and eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar, or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar, or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.
I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/ We satisfy, and each account for which I/ we are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence. I/ we hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 126.
I/ We acknowledge that the Company, their affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.
Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar at www.skylinertat.com.
Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date
Selling Restrictions: The distribution of this Letter of Offer, Application Form and the Rights Entitlement Letter ("Issue Materials") and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.
Notice To Investors: No action has been or will be taken to permit the Issue in any jurisdiction where any action would be required for that purpose. Accordingly, the Rights Entitlements or Rights Equity Shares may not be offered or sold, directly or indirectly, and the Issue Material or any offering materials or advertisements in connection with the Issue may not be distributed, in whole or in part, in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of the Issue Material will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer and, in those circumstances, the Issue Material must be treated as sent for information purposes only and should not be acted upon for subscription to the Rights Equity Shares and should not be coupled or redistributed. Accordingly, persons receiving a copy of the Issue Material should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send the Issue Material to any person outside India where to do so, would or might contravene local securities laws or regulations. If the Issue Material is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to subscribe to the Rights Equity Shares or the Rights Entitlements referred to in the Issue Material.
Any person who makes an application to acquire the Rights Entitlements or the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements or the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in his jurisdiction. Our Company, the Registrar or any other person acting on behalf of our Company reserves the right to treat any Application Form as invalid where they believe that Application Form is incomplete or acceptance of such Application Form may infringe applicable legal or regulatory requirements and we shall not be bound to allot or issue any Rights Equity Shares or Rights Entitlement in respect of any such Application Form.
THE RIGHTS ENTITLEMENTS AND THE RIGHTS EQUITY SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ACCORDINGLY, THE RIGHTS EQUITY SHARES ARE ONLY

BEING OFFERED AND SOLD IN "OFFSHORE TRANSACTIONS" AS DEFINED IN, AND IN RELIANCE ON, REGULATIONS UNDER THE U.S. SECURITIES ACT TO ELIGIBLE EQUITY SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE IS PERMITTED UNDER THE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THE DRAFT LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY RIGHTS ENTITLEMENTS OR RIGHTS EQUITY SHARES FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY ANY OF THE SAID SECURITIES. ACCORDINGLY, YOU SHOULD NOT FORWARD OR TRANSMIT THE LETTER OF OFFER INTO THE UNITED STATES AT ANY TIME.

Neither our Company nor any person acting on our behalf will accept a subscription or renunciation from any person, or the agent of any person, who appears to be, or who our Company or any person acting on our behalf has reason to believe is in the United States when the buy order is made. Envelopes containing an Application Form and Rights Entitlement Letter should not be postmarked in the United States or otherwise dispatched from the United States or any other jurisdiction where it would be illegal to make an offer, and all persons subscribing for the Rights Equity Shares issue and wishing to hold such Equity Shares in registered form must provide an address for registration of these Equity Shares in India.
Rights Entitlements may not be transferred or sold to any person in the United States.
Last Date For Application: The last date for submission of the duly filled in the Application Form or a plain paper Application is Wednesday, September 02, 2026, i.e., Issue Closing Date. Our Board thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).
If the Application together with the amount payable is either (i) not blocked with an SCSB; or (ii) not received by the Registrar on or before the close of banking hours on the Issue Closing Date or such date as may be extended by our Board the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as provided under "Terms of the Issue - Basis of Allotment" on page 119 of the Letter of Offer. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 05:00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.
Allotment Only In Dematerialised Form: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Sunrest Lifescience Limited – Right Issue Escrow Entitlement Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (6) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.
Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e. Wednesday, September 02, 2026, to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar is active to facilitate the aforementioned transfer.
INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM. FURTHER NOTE THAT IF NO APPLICATION IS MADE BY THE ELIGIBLE SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO EQUITY SHARES FOR SUCH LAPSED RIGHTS ENTITLEMENTS WILL BE CREDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM SECONDARY MARKET PLATFORM OF THE STOCK EXCHANGE (THE ON MARKET RENUNCIATION) OR THROUGH AN OFF MARKET TRANSFER (THE OFF MARKET RENUNCIATION) DURING THE RENUNCIATION PERIOD AND PURCHASER WILL LOSE THE PREMIUM PAID TO ACQUIRE THE RIGHTS ENTITLEMENTS. PERSONS WHO ARE CREDITED THE RIGHTS ENTITLEMENTS ARE REQUIRED TO MAKE AN APPLICATION TO APPLY FOR EQUITY SHARES OFFERED UNDER RIGHTS ISSUE FOR SUBSCRIBING TO THE EQUITY SHARES OFFERED UNDER THIS ISSUE. OUR COMPANY ACCEPTS NO RESPONSIBILITY TO BEAR OR PAY ANY COST APPLICABLE TAXES, CHARGES AND EXPENSES (INCLUDING BROKERAGE) AND SUCH COSTS WILL BE INCURRED SOLELY BY THE SHAREHOLDERS.
DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 93 of the LOF.
DISCLAIMER CLAUSE OF NSEI (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by National Stock Exchange of India Limited ("NSEI") should not in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by NSEI, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" on page 94 of the Letter of Offer.
Banker To The Issue And Refund Bank: Axis Bank Limited
Monitoring Agency: Our Company has appointed Brickwork Ratings Private Limited as the Monitoring Agency for the purpose of monitoring and the utilisation of the net proceeds.
Dispatch And Availability Of Issue Materials: In accordance with the SEBI ICDR Regulations and SEBI Master Circular, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/dispatched only to Eligible Equity Shareholders who have provided their Indian address to our Company and who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian